Business Standard

AstraZeneca finds small clot risk after first dose of Vaxzevria vaccine

No extra risk after second dose shows study led and funded by drug maker

Photo: Bloomberg
Premium

Vaxzevria is made in India by Pune based Serum Institute of India (SII) and marketed as Covishield. Photo: Bloomberg

Sohini Das Mumbai
British-Swedish drugmaker AstraZeneca said that its Covid-19 vaccine Vaxzevria carries a small extra risk of rare blood clots with low platelets after the first dose, but no extra risk after the second shot.

A study led and funded by the drugmaker which was published in the Lancet medical journal found that the estimated rate of thrombosis with thrombocytopenia (TTS) after the first dose was 8.1 per million in those vaccinated.

Vaxzevria is made in India by Pune based Serum Institute of India (SII) and marketed as Covishield.

The vaccine which is co-developed by the University of Oxford, the AstraZeneca vaccine

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in